RSV ACIP Vaccine Recommendations
Advisory Committee on Immunization Practices (ACIP)
On This Page
Published in Morbidity and Mortality Weekly Report (MMWR)
The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CDC Director and, if adopted, are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).
CURRENT RSV Vaccine Recommendations
- MMWR; October 13, 2023 / 72(41);1115–1122
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
Print version [8 pages] - MMWR; August 25, 2023 / 72(34);920–925
Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
Print version [6 pages]- See also:
- GRADE: Nirsevimab, Season 1 | CDC
- ACIP Evidence to Recommendations for Use of Nirsevimab in Infants born during the RSV season or entering their first RSV season | CDC
- GRADE: Nirsevimab, Season 2 | CDC
- ACIP Evidence to Recommendations for Use of Nirsevimab in Children 8–19 months of age with increased risk of severe disease entering their second RSV season | CDC
- See also:
- MMWR; July 21, 2023;72(29);793–801
Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
Print version [9 pages]- See also:
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): GSK RSVPreF3 Vaccine (AREXVY) | CDC
- ACIP Evidence to Recommendations for Use of GSK Adjuvanted RSVPreF3 Vaccine (AREXVY) in Adults Ages 60 and Older | CDC
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer RSVpreF Vaccine (ABRYSVO) | CDC
- ACIP Evidence to Recommendations for Use of Pfizer Bivalent RSVpreF Vaccine (ABRSYVO) in Older Adults | CDC
- See also:
ARCHIVED RSV Immunization Publications
For your convenience, these archived publications can be used for historical and research purposes.
- No archived articles at this time.